1548 — Genscript Biotech Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$22.15bn
- HK$15.45bn
- $839.53m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -114 | -282 | -496 | -432 | -351 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 1.96 | 105 | 186 | 60.8 | 23.5 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 61.2 | -6.49 | 126 | 186 | -33.4 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -30 | -151 | -137 | -120 | -287 |
Capital Expenditures | -112 | -128 | -137 | -204 | -158 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -96.9 | 27.6 | -75.2 | -240 | -200 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -209 | -100 | -213 | -443 | -358 |
Financing Cash Flow Items | -5.58 | -8.67 | -0.194 | -29.7 | -2.24 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -2.78 | 624 | 902 | 419 | 1,068 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -242 | 377 | 552 | -157 | 422 |